drugset / Trial / NCT02090127
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Summary
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ficlatuzumab | Monoclonal antibody | 16.5 mg/kg | Intravenous |